BIOSIMILAR

FEGO Biotech main focus is in immunology therapy and managing autoimmune diseases. We are a “clinical-stage” biotech company, with a strong focus on Biosimilars. This is not just a business revenue area but importantly an “aid” helping human beings to have a healthier lifespan. Biosimilars are generic versions of existing Biologics of innovator-drugs upon patents expiry and we hope to hold one of the largest biosimilars portfolios in Singapore in monoclonal antibodies and other biologics for virology, oncology, immunology and other therapeutic cures.

 

We are well positioned to offer these highly innovative drugs or medicines at cheaper costs. The demand for biosimilars is set to grow as the reference patents expire on leading biologics and more patients demand lower priced drugs. FEGO Biotech is partnering with several international clinical-stage companies for their own researched biosimilars with cutting edge platform technologies. With long term collaboration in joint research and market distribution for market in ASEAN, FEGO aims to set up a fill-finish plant unit in Singapore for innovative biologics and Biosimilars.  We are constantly in discussion with Chinese pharmaceutical firms as well.

 

​

Biosimilars in the pipeline

​

• The two leading candidates – FEGDP1 AND FEGDP2.

 

• FEGDP1 – It is a biosimilar version of Adalimumab, – a TNF Inhibitor intended to treat patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis and plaque psoriasis. FEGO comes with its own brand and we are working closely with established research group on this as we try to launch it in 2022.

 

• FEGDP2 – It is a biosimilar version of Trastuzumab- the best available medicine for breast cancer with HER-2 receptor positive. FEGO’s biosimilar version will work on itself or in combination with chemotherapy products.

 

• FEGDP3 – Ranibizumab is a recombinant humanized monoclonal antibody and VEGF-A antagonist used for the management of macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema.

 

• FEGDP4 – Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A)

 

• FEGDP5 – Denosumab injection is in a class of medications called RANK ligand inhibitors. It works to prevent bone loss by blocking a certain receptor in the body to decrease bone breakdown. It works to treat GCTB by blocking a certain receptor in the tumor cells which slows the tumor growth. It works to treat high calcium levels by decreasing bone breakdown as the breakdown of bones releases calcium

 

• FEGDP6 – Liraglutide is an anti-diabetic medication used to treat type 2 diabetes, obesity, and chronic weight management.

 

• FEGDP7 – Ipilimumab is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system